On January 7th, the Fourth Chinese Hematology Development Conference unveiled the “Top 10 Research Advances in Chinese Hematology in 2023.”
The selection of the "Top 10 Research Advances in Chinese Hematology" is initiated by the Chinese Hematology Development Conference, and it has been successfully held for four sessions since 2020. Its purpose is to document, show case, and promote significant scientific advancements and landmark achievements in the field of hematology research in China. This initiative aims to demonstrate the strength and academic level of hematology research in China, inspire hematologists and scientists to take on greater missions and pursue excellence, and foster public understanding, concern, and support for hematology research, creating a favorable scientific atmosphere throughout society.
The scientific advancements recommended as the “Top 10 Research Advances in Chinese Hematology in 2023” were all research outcomes publicly disclosed between January 1st and December 31st of 2023, with core scientific discoveries conducted in China. The organizing committee of the Chinese Hematology Development Conference invited nominations from 78 experts in 16 subcategories of hematology. After multiple rounds of organization and extensive recommendations from experts, 19 advancements were selected for the final round. The final selection process involved online voting, with participation from academicians from relevant institutions, the Hematology Subsociety of the Chinese Medical Association, the Experimental Hematology Special Committee of the Chinese Physiological Society, the Hematological Physiology Special Committee of the Chinese Physiological Society, the Hematologic Oncology Special Committee of the Chinese Anti-Cancer Association, the Hematology Institutions Subsociety of the Chinese Hospital Association, the Working Committee of the Chinese Hematology Specialized Alliance, the Editorial Committee of “Chinese Journal of Hematology,” and Chinese editorial board members of “Blood Science.” A total of 126 valid votes were received, and the top 10 advancements with the highest number of votes were selected as the “Top 10 Research Advances in Chinese Hematology in 2023.” These selected advancements encompass both clinical and basic research, featuring outstanding originality, distinct innovation, and significant societal impact.
1. Ex utero monkey embryogenesis from blastocyst to early organogenesis
Key Technologies, Applications, Deep Exploration, Earth Science
Funded Projects: Deep Exploration Technologies and Experimentation
Project Leaders: [Names and affiliations redacted for privacy]
2. PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia
Basic Theory, Applied Technology, Quantum Information
Funded Projects: Research on Quantum Information Technologies
Project Leaders: [Names and affiliations redacted for privacy
3. ①Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.
②Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.3
High-performance, Large-scale Production, Carbon Materials, Application Technology
Funded Projects: High-Performance Carbon Materials Large-scale Production and Application (M-HOPES)
Project Leaders: [Names and affiliations redacted for privacy]
4. Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1.
Synthetic Biology, Field, Innovative Development
Funded Projects: Synthetic Biology Field Innovation
Project Leaders: [Names and affiliations redacted for privacy]
5. Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation
Funded Projects: Brain-like Computing Chips and Brain-computer Fusion Technology
Project Leaders: [Names and affiliations redacted for privacy]
6. A pan-cancer single-cell panorama of human natural killer cells.
Ultra-high Temperature, Materials, Extreme Environments, Application
Funded Projects: Research on Ultra-high Temperature Materials and Applications
Project Leaders: [Names and affiliations redacted for privacy]
7. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
Precision Treatment, Cancer, Fourth Generation, CAR-T
Funded Projects: GPRC5D CAR-T Clinical Application Breakthrough
Project Leaders: [Names and affiliations redacted for privacy]
8. Multi-omics blood atlas reveals unique features of immune and platelet responses to SARS-CoV-2 Omicron breakthrough infection.
Large-scale Device, Construction, Earth System, Comprehensive Research
Funded Projects: Construction of a Large Device for Comprehensive Earth System Research
Project Leaders: [Names and affiliations redacted for privacy]
9. ①Excessive serine from the bone marrow microenvironment impairs megakaryopoiesis and thrombopoiesis in Multiple Myeloma.
②Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Basic Theory, Engineering Technology, Nano Energy, Materials and Devices
Funded Projects: Basic Theory and Engineering Technology of Nano Energy Materials and Devices
Project Leaders: [Names and affiliations redacted for privacy]
10. STING activation in platelets aggravates septic thrombosis by enhancing platelet activation and granule secretion.
Testing Technology, Marine Resources, Environment, Large-scale Research Vessel
Funded Projects: Marine Resources and Environment Testing Technology Based on Large Research Vessel Operations
The year 2024 is a crucial year for fully implementing the spirit of the 20th National Congress of the Communist Party of China and for advancing the objectives of the “14th Five-Year Plan.” To carry out the new development philosophy, build a new development pattern, and promote high-quality development, scientific and technological solutions are needed more than ever before, and innovation must be strengthened as the primary driving force. The Chinese Hematology Development Conference has always been committed to promoting an active academic atmosphere in the field of hematology in China, upholding the scientific spirit, fostering innovation confidence, seizing innovation opportunities, scaling scientific and technological peaks, and tackling development challenges. It aims to accelerate high-level technological self-reliance, promote global scientific progress, and contribute more Chinese wisdom and solutions to safeguarding public health and achieving a shared future for humanity.
